{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T18:12:51.251265+00:00","company":{"ticker":"REGN","cik":872589,"company_name":"REGENERON PHARMACEUTICALS, INC."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"a0ca34418e57efd385a5cbbf1386c4615f061ef7","cik":872589,"ticker":"REGN","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-04-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter 2026","report_date":"2026-04-08","result_type":"preliminary_results","revenue_text":null},"claim":"REGENERON PHARMACEUTICALS, INC. reported preliminary financial results for first quarter 2026.","evidence_excerpt":"Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001104659-26-040661","anchor_url":"https://secwatch.observer/filing/0001104659-26-040661#claim-a0ca34418e57efd385a5cbbf1386c4615f061ef7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/0001104659-26-040661-index.htm"},{"fact_type":"earnings_release","fact_key":"94ed913b0d4c5b6ce4c03f22eed710417df544ea","cik":872589,"ticker":"REGN","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter of 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":null},"claim":"REGENERON PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.","evidence_excerpt":"On May 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001804220-24-000015","anchor_url":"https://secwatch.observer/filing/0001804220-24-000015#claim-94ed913b0d4c5b6ce4c03f22eed710417df544ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/0001804220-24-000015-index.htm"}]}